LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Kodu・Aktsiate loetelu・SCYNEXIS Inc

SCYNEXIS Inc

Suletud

0.8 -3.61

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.8

Max

0.82

Põhinäitajad
By Trading Economics
Sissetulek	21M 12M
Müük	18M 19M
Kasumimarginaal	65.741
Töötajad	18
EBITDA	11M 11M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+316.67% upside

Turustatistika
By TradingEconomics
Turukapital	7.7M 39M
Eelmine avamishind	4.41
Eelmine sulgemishind	0.8

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

0.9307 / 0.9907 Toetus ja vastupanu

SCYNEXIS Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. märts 2026, 17:33 UTC

Uudisväärsed sündmused

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27. märts 2026, 17:00 UTC

Uudisväärsed sündmused

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27. märts 2026, 16:03 UTC

Uudisväärsed sündmused

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27. märts 2026, 14:50 UTC

Suurimad hinnamuutused turgudel

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27. märts 2026, 14:37 UTC

Omandamised, ülevõtmised, äriostud

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27. märts 2026, 14:29 UTC

Uudisväärsed sündmused

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27. märts 2026, 14:16 UTC

Uudisväärsed sündmused

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 19:16 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27. märts 2026, 19:07 UTC

Market Talk

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27. märts 2026, 19:04 UTC

Market Talk

Gold Rises But Can't Finish the Week Positive -- Market Talk

27. märts 2026, 19:03 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 19:02 UTC

Market Talk

Uudisväärsed sündmused

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27. märts 2026, 18:12 UTC

Market Talk

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27. märts 2026, 17:36 UTC

Uudisväärsed sündmused

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27. märts 2026, 17:34 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27. märts 2026, 17:29 UTC

Market Talk

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27. märts 2026, 16:38 UTC

Market Talk

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27. märts 2026, 16:32 UTC

Market Talk

Uudisväärsed sündmused

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27. märts 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 15:43 UTC

Market Talk

Uudisväärsed sündmused

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27. märts 2026, 15:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 15:25 UTC

Market Talk

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27. märts 2026, 15:00 UTC

Uudisväärsed sündmused

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27. märts 2026, 15:00 UTC

Uudisväärsed sündmused

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27. märts 2026, 15:00 UTC

Uudisväärsed sündmused

Fed's Barkin Says Iran War Raising Economic Uncertainty

27. märts 2026, 14:36 UTC

Market Talk

Uudisväärsed sündmused

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27. märts 2026, 14:26 UTC

Market Talk

Uudisväärsed sündmused

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27. märts 2026, 14:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 14:14 UTC

Market Talk

Global Energy Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

SCYNEXIS Inc Prognoos

Hinnasiht

By TipRanks

316.67% tõus

12 kuu keskmine prognoos

Keskmine 3.5 USD 316.67%

Kõrge 4 USD

Madal 3 USD

Põhineb 2 Wall Streeti analüütiku instrumendi SCYNEXIS Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi SCYNEXIS Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9307 / 0.9907Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.